J M Reichert

Summary

Affiliation: Tufts University
Country: USA

Publications

  1. ncbi request reprint Therapeutic monoclonal antibodies: trends in development and approval in the US
    Janice M Reichert
    Tufts Center for the Study of Drug Development, Boston, MA 02111, USA
    Curr Opin Mol Ther 4:110-8. 2002
  2. pmc Antibody-based therapeutics to watch in 2011
    Janice M Reichert
    Tufts Center for the Study of Drug Development, Boston, MA, USA
    MAbs 3:76-99. 2011
  3. ncbi request reprint Technology evaluation: lumiliximab, Biogen Idec
    Janice M Reichert
    Tufts Center for the Study of Drug Development, 192 South Street, Suite 550, Boston, MA 02111, USA
    Curr Opin Mol Ther 6:675-83. 2004
  4. ncbi request reprint Trends in development and approval times for new therapeutics in the United States
    Janice M Reichert
    Tufts Center for the Study of Drug Development, 192 South Street, Suite 550, Boston, Massachussets 02111, USA
    Nat Rev Drug Discov 2:695-702. 2003
  5. ncbi request reprint Trends in US approvals: new biopharmaceuticals and vaccines
    Janice M Reichert
    Tufts Center for the Study of Drug Development, Boston, MA 02111, USA
    Trends Biotechnol 24:293-8. 2006
  6. doi request reprint The future of antibodies as cancer drugs
    Janice M Reichert
    Center for the Study of Drug Development, Tufts University School of Medicine, 75 Kneeland Street, Suite 1100, Boston, MA 02111, USA
    Drug Discov Today 17:954-63. 2012
  7. ncbi request reprint Trends in the development and approval of monoclonal antibodies for viral infections
    Janice M Reichert
    Tufts University, Tufts Center for the Study of Drug Development, Boston, Massachusetts 02111, USA
    BioDrugs 21:1-7. 2007
  8. ncbi request reprint Development trends for monoclonal antibody cancer therapeutics
    Janice M Reichert
    Tufts Center for the Study of Drug Development, Tufts University, 192 South Street, Suite 550, Boston, Massachusetts 02111, USA
    Nat Rev Drug Discov 6:349-56. 2007
  9. doi request reprint Development trends for new cancer therapeutics and vaccines
    Janice M Reichert
    Tufts Center for the Study of Drug Development, 75 Kneeland Street, Suite 1100, Boston, MA 02111, United States
    Drug Discov Today 13:30-7. 2008
  10. doi request reprint A decade of the Fast Track programme
    Janice M Reichert
    Janice M Reichert and Stephanie L Rochon are at the Tufts Center for the Study of Drug Development, 75 Kneeland Street, Suite 1100, Boston, Massachusetts 02111, USA
    Nat Rev Drug Discov 7:885-6. 2008

Detail Information

Publications28

  1. ncbi request reprint Therapeutic monoclonal antibodies: trends in development and approval in the US
    Janice M Reichert
    Tufts Center for the Study of Drug Development, Boston, MA 02111, USA
    Curr Opin Mol Ther 4:110-8. 2002
    ..In addition, mAbs that are either in phase III, FDA-review, or are FDA approved for antineoplastic or immunological indications are described...
  2. pmc Antibody-based therapeutics to watch in 2011
    Janice M Reichert
    Tufts Center for the Study of Drug Development, Boston, MA, USA
    MAbs 3:76-99. 2011
    ..Current as of September 2010, the information presented here will serve as a baseline against which future progress in the development of antibody-based therapeutics can be measured...
  3. ncbi request reprint Technology evaluation: lumiliximab, Biogen Idec
    Janice M Reichert
    Tufts Center for the Study of Drug Development, 192 South Street, Suite 550, Boston, MA 02111, USA
    Curr Opin Mol Ther 6:675-83. 2004
    ..Biogen Idec (formerly IDEC Pharmaceuticals) is developing lumiliximab, a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions...
  4. ncbi request reprint Trends in development and approval times for new therapeutics in the United States
    Janice M Reichert
    Tufts Center for the Study of Drug Development, 192 South Street, Suite 550, Boston, Massachussets 02111, USA
    Nat Rev Drug Discov 2:695-702. 2003
    ..Current efforts by the FDA, and the pharmaceutical and biopharmaceutical industry, to reverse the recent tendency toward fewer new approvals and longer approval times are discussed...
  5. ncbi request reprint Trends in US approvals: new biopharmaceuticals and vaccines
    Janice M Reichert
    Tufts Center for the Study of Drug Development, Boston, MA 02111, USA
    Trends Biotechnol 24:293-8. 2006
    ..We predict that this might change in the future as government and industry respond to the twin threats of the global spread of infectious diseases and potential bioterrorism...
  6. doi request reprint The future of antibodies as cancer drugs
    Janice M Reichert
    Center for the Study of Drug Development, Tufts University School of Medicine, 75 Kneeland Street, Suite 1100, Boston, MA 02111, USA
    Drug Discov Today 17:954-63. 2012
    ....
  7. ncbi request reprint Trends in the development and approval of monoclonal antibodies for viral infections
    Janice M Reichert
    Tufts University, Tufts Center for the Study of Drug Development, Boston, Massachusetts 02111, USA
    BioDrugs 21:1-7. 2007
    ..Public sector research into the use of mAbs against emerging pathogens, such as severe acute respiratory syndrome coronavirus, may have already provided candidates for further development...
  8. ncbi request reprint Development trends for monoclonal antibody cancer therapeutics
    Janice M Reichert
    Tufts Center for the Study of Drug Development, Tufts University, 192 South Street, Suite 550, Boston, Massachusetts 02111, USA
    Nat Rev Drug Discov 6:349-56. 2007
    ..Here, we overview trends in the clinical development and regulatory approval of monoclonal antibodies for cancer since 1980, with the aim of informing future research and development for this class of therapeutics...
  9. doi request reprint Development trends for new cancer therapeutics and vaccines
    Janice M Reichert
    Tufts Center for the Study of Drug Development, 75 Kneeland Street, Suite 1100, Boston, MA 02111, United States
    Drug Discov Today 13:30-7. 2008
    ..These results indicate that improvement in the efficiency of the development process for innovative cancer treatments is needed...
  10. doi request reprint A decade of the Fast Track programme
    Janice M Reichert
    Janice M Reichert and Stephanie L Rochon are at the Tufts Center for the Study of Drug Development, 75 Kneeland Street, Suite 1100, Boston, Massachusetts 02111, USA
    Nat Rev Drug Discov 7:885-6. 2008
  11. ncbi request reprint Monoclonal antibodies as innovative therapeutics
    Janice M Reichert
    Senior Research Fellow, Tufts University, Tufts Center for the Study of Drug Development, 75 Kneeland Street, Suite 1100, Boston, MA 02111, USA
    Curr Pharm Biotechnol 9:423-30. 2008
    ..Trends in these benchmarks for various types of mAbs, with an emphasis on those studied as anticancer and immunological therapeutics, are discussed...
  12. doi request reprint Finding value in the U.S. Food and Drug Administration's Fast Track program
    Janice M Reichert
    Tufts Center for the Study of Drug Development, Boston, Massachusetts 02111, USA
    Drug News Perspect 22:53-8. 2009
    ..Our results suggest that evaluation of the Fast Track program requires a nuanced approach, and estimates of the program's value should include assessment of the resulting marketed products...
  13. doi request reprint Second International Conference on Accelerating Biopharmaceutical Development: March 9-12, 2009, Coronado, CA, USA
    Janice M Reichert
    Tufts Center for the Study of Drug Development, 75 Kneeland Street, Suite 1100, Boston, MA 02111, USA
    Biotechnol Prog 25:1198-215. 2009
    ....
  14. pmc Second International Conference on Accelerating Biopharmaceutical Development: March 9-12, 2009, Coronado, CA USA
    Janice M Reichert
    Tufts Center for the Study of Drug Development Boston, MA 02111, USA
    MAbs 1:190-209. 2009
    ....
  15. pmc Antibodies to watch in 2010
    Janice M Reichert
    Tufts Center for the Study of Drug Development, Boston, MA, USA
    MAbs 2:84-100. 2010
    ..Current as of October 2009, the results presented here will serve as a baseline against which future progress can be measured...
  16. ncbi request reprint Anti-infective monoclonal antibodies: perils and promise of development
    Janice M Reichert
    Tufts University, Tufts Center for the Study of Drug Development, 192 South Street, Suite 550, Boston, Massachusetts 02111, USA
    Nat Rev Drug Discov 5:191-5. 2006
    ..Here, we analyse trends in the development and approval of anti-infective monoclonal antibodies, and discuss factors that influence their success...
  17. ncbi request reprint Monoclonal antibody successes in the clinic
    Janice M Reichert
    Tufts University Center for the Study of Drug Development CSDD, 192 South Street, Suite 550, Boston, Massachusetts 02111, USA
    Nat Biotechnol 23:1073-8. 2005
    ..Most monoclonal antibodies in clinical trials are owned by small biotech companies. But with blockbuster-sized revenues and approval rates higher than those for small-molecule drugs, that all may be set to change...
  18. ncbi request reprint Biopharmaceuticals approved in the EU 1995-1999: a European Union-United States comparison
    J M Reichert
    Tufts Center for the Study of Drug Development, Boston, MA 02111, USA
    Eur J Pharm Biopharm 51:1-7. 2001
    ..We compared EU and US approval times for these products by product category and by review status (exceptional/non-exceptional circumstance in the EU and priority/standard in the US)...
  19. ncbi request reprint Therapeutic cancer vaccines on trial
    Janice M Reichert
    Tufts Center for the Study of Drug Development, Boston, MA, USA
    Nat Biotechnol 20:659-63. 2002
  20. ncbi request reprint Public and private sector contributions to the discovery and development of "impact" drugs
    Janice M Reichert
    Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts 02111, USA
    Am J Ther 9:543-55. 2002
    ..What remains clear, however, is that the process still starts with good science and ends with good medicine...
  21. ncbi request reprint Therapeutic recombinant proteins: trends in US approvals 1982 to 2002
    Janice M Reichert
    Tufts Center for the Study of Drug Development, Suite 550, 192 South Street, Boston, MA 02111, USA
    Curr Opin Mol Ther 5:139-47. 2003
    ..Approval success rates, calculated using three methods that differ only in the definition of success, and the variation of approval success rates over five time periods are presented...
  22. ncbi request reprint Clinical development of therapeutic recombinant proteins
    Janice M Reichert
    Tufts Center for the Study of Drug Development, Boston, MA, USA
    Biotechniques 35:176-8, 180, 182-5. 2003
    ..S. approval success rates ranged from 17% to 58%. Trends in clinical phase lengths over five time periods and an overview of the rDNA therapeutics currently under Food and Drug Administration review are discussed...
  23. ncbi request reprint New biopharmaceuticals in the USA: trends in development and marketing approvals 1995-1999
    J M Reichert
    Tufts Center for the Study of Drug Development, 192 South Street, Suite 550, Boston, MA 02111, USA
    Trends Biotechnol 18:364-9. 2000
    ..They are also compared with the data for approvals during the periods 1982-1989, 1990-1994 and 1996-1998...
  24. pmc European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK
    Janice M Reichert
    Tufts Center for the Study of Drug Development, Boston, MA, USA
    MAbs 1:394-416. 2009
    ..Proceedings of the workshop are presented in Part 1 of this report, and discussed within the context of the legal, regulatory and business environments of the European Union, Asia and the United States in Parts 2, 3 and 4, respectively...
  25. ncbi request reprint Current trends in the clinical development of peptide therapeutics
    Pauline M Saladin
    Harvard University, Department of Health Policy and Management, School of Public Health, Kresge 4th floor, 677 Huntington Avenue, Boston, MA 02115, USA
    IDrugs 12:779-84. 2009
    ..The results provide an historical overview of the development of peptide therapeutics, and may inform strategic planning in this area...
  26. doi request reprint Development trends for human monoclonal antibody therapeutics
    Aaron L Nelson
    Tufts University School of Medicine, Boston, Massachusetts 02118, USA
    Nat Rev Drug Discov 9:767-74. 2010
    ..Here, we analyse data on 147 human mAbs that have entered clinical study to highlight trends in their development and approval, which may help inform future studies of this class of therapeutic agents...
  27. ncbi request reprint Recombinant protein therapeutics--success rates, market trends and values to 2010
    Alex K Pavlou
    Datamonitor plc, Charles House 108 110 Finchley Road, London, UK
    Nat Biotechnol 22:1513-9. 2004
  28. ncbi request reprint Trends in the development of therapeutic anti-cytokine antibodies
    Janice M Reichert
    Drug Discov Today 9:348. 2004